Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

Enrique Grande, José Arranz, Maria De Santis, Aristotelis Bamias, Eiji Kikuchi, Xavier Garcia del Muro, Se Hoon Park, Ugo De Giorgi, Boris Alekseev, Marina Mencinger, Kouji Izumi, Fabio A. Schutz, Javier Puente, Jian Ri Li, Peter H. O'Donnell, Arash Rezazadeh Kalebasty, Dingwei Ye, Sanjeev Mariathasan, Fabio Ia Bene-Tchaleu, Sandrine BernhardChooi Lee, Ian D. Davis, Matthew D. Galsky

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Fingerprint

Dive into the research topics of 'Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology